- Home
- UFCS vs ETON Comparison
UFCS vs ETON Comparison
Compare UFCS & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UFCS | ETON |
|---|---|---|
| Founded | 1946 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 1995 | 2018 |
Fundamental Metrics
Financial Performance| Metric | UFCS | ETON |
|---|---|---|
| Price | $51.23 | $69.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $57.50 | ★ $80.75 |
| AVG Volume (30 Days) | 123.8K | ★ 474.8K |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.55% | N/A |
| EPS Growth | ★ 87.45 | N/A |
| EPS | ★ 3.78 | 1.48 |
| Revenue | ★ $1,386,412,000.00 | $79,950,000.00 |
| Revenue This Year | $15.24 | $125.03 |
| Revenue Next Year | $19.13 | $59.47 |
| P/E Ratio | ★ $13.71 | $46.01 |
| Revenue Growth | 10.62 | ★ 104.94 |
| 52 Week Low | $33.53 | $14.27 |
| 52 Week High | $58.20 | $68.38 |
Technical Indicators
Market Signals| Indicator | UFCS | ETON |
|---|---|---|
| Relative Strength Index (RSI) | 40.83 | 72.96 |
| Support Level | $48.44 | $48.58 |
| Resistance Level | $55.12 | N/A |
| Average True Range (ATR) | 2.17 | 3.64 |
| MACD | -0.73 | 2.12 |
| Stochastic Oscillator | 39.84 | 88.86 |
Price Performance
Historical ComparisonAbout UFCS United Fire Group Inc.
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.